Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors

NCT03517956 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03517956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03517956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
July 25, 2018
Completion date
February 1, 2021
Enrollment
16 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumor